Phase II Single Arm, Open Label, Single Institution Study of Continuous Sunitinib (Sutent) in Patients With High-Risk (BCG-Refractory) Superficial Transitional Cell Carcinoma (TCC) of the Bladder
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Sunitinib (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- 24 Jun 2019 Primary endpoint (Complete response rate) has not been met, according to the results published in the Investigational New Drugs.
- 24 Jun 2019 Results published in the Investigational New Drugs
- 17 Apr 2019 Status changed from completed to discontinued.